Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322758317> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4322758317 abstract "Janus kinase 2 inhibitors (JAKi) are now part of the therapeutic armamentarium for primary and secondary myelofibrosis (MF). Patients with MF endure shortened survival and poor quality of life (QoL). Allogeneic stem cell transplant is currently the only treatment modality in MF with the potential to cure the disease or prolong survival. By contrast, current drug therapy in MF targets QoL and does not modify the natural history of the disease. The discovery of JAK2 and other JAK-STAT activating mutations (i.e., CALR and MPL) in myeloproliferative neoplasms, including MF, has facilitated the development of several JAKi that are not necessarily specific to the oncogenic mutations themselves but proved effective in countering JAK-STAT signaling, resulting in suppression of inflammatory cytokines and myeloproliferation. This non-specific activity resulted in clinically favorable effects on constitutional symptoms and splenomegaly and, consequently, FDA approval of three small molecule JAKi: ruxolitinib, fedratinib, and pacritinib. A fourth JAKi, momelotinib, is poised for FDA approval soon and has been shown to provide additional benefit in alleviating transfusiondependent anemia in MF. The salutary effect of momelotinib on anemia has been attributed to inhibition of activin A receptor, type 1 (ACVR1) and recent information suggests similar effect from pacritinib. ACRV1 mediates SMAD2/3 signalling that contributes to upregulation of hepcidin production and iron-restricted erythropoiesis. Therapeutic targeting of ACRV1 raises therapeutic prospects in other myeloid neoplasms associated with ineffective erythropoiesis, such as myelodysplastic syndromes with ring sideroblasts or SF3B1 mutation, especially those with co-expression of JAK2 mutation and thrombocytosis." @default.
- W4322758317 created "2023-03-03" @default.
- W4322758317 creator A5002643270 @default.
- W4322758317 creator A5016216479 @default.
- W4322758317 creator A5024612499 @default.
- W4322758317 date "2023-03-02" @default.
- W4322758317 modified "2023-10-05" @default.
- W4322758317 title "Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis" @default.
- W4322758317 doi "https://doi.org/10.3324/haematol.2022.282612" @default.
- W4322758317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36861402" @default.
- W4322758317 hasPublicationYear "2023" @default.
- W4322758317 type Work @default.
- W4322758317 citedByCount "6" @default.
- W4322758317 countsByYear W43227583172023 @default.
- W4322758317 crossrefType "journal-article" @default.
- W4322758317 hasAuthorship W4322758317A5002643270 @default.
- W4322758317 hasAuthorship W4322758317A5016216479 @default.
- W4322758317 hasAuthorship W4322758317A5024612499 @default.
- W4322758317 hasBestOaLocation W43227583171 @default.
- W4322758317 hasConcept C112392421 @default.
- W4322758317 hasConcept C126322002 @default.
- W4322758317 hasConcept C170493617 @default.
- W4322758317 hasConcept C203014093 @default.
- W4322758317 hasConcept C2776112149 @default.
- W4322758317 hasConcept C2778248108 @default.
- W4322758317 hasConcept C2778690821 @default.
- W4322758317 hasConcept C2779703530 @default.
- W4322758317 hasConcept C2779788118 @default.
- W4322758317 hasConcept C2780007613 @default.
- W4322758317 hasConcept C2780076729 @default.
- W4322758317 hasConcept C2780817109 @default.
- W4322758317 hasConcept C2910274570 @default.
- W4322758317 hasConcept C32465701 @default.
- W4322758317 hasConcept C502942594 @default.
- W4322758317 hasConcept C71924100 @default.
- W4322758317 hasConcept C89560881 @default.
- W4322758317 hasConceptScore W4322758317C112392421 @default.
- W4322758317 hasConceptScore W4322758317C126322002 @default.
- W4322758317 hasConceptScore W4322758317C170493617 @default.
- W4322758317 hasConceptScore W4322758317C203014093 @default.
- W4322758317 hasConceptScore W4322758317C2776112149 @default.
- W4322758317 hasConceptScore W4322758317C2778248108 @default.
- W4322758317 hasConceptScore W4322758317C2778690821 @default.
- W4322758317 hasConceptScore W4322758317C2779703530 @default.
- W4322758317 hasConceptScore W4322758317C2779788118 @default.
- W4322758317 hasConceptScore W4322758317C2780007613 @default.
- W4322758317 hasConceptScore W4322758317C2780076729 @default.
- W4322758317 hasConceptScore W4322758317C2780817109 @default.
- W4322758317 hasConceptScore W4322758317C2910274570 @default.
- W4322758317 hasConceptScore W4322758317C32465701 @default.
- W4322758317 hasConceptScore W4322758317C502942594 @default.
- W4322758317 hasConceptScore W4322758317C71924100 @default.
- W4322758317 hasConceptScore W4322758317C89560881 @default.
- W4322758317 hasLocation W43227583171 @default.
- W4322758317 hasLocation W43227583172 @default.
- W4322758317 hasOpenAccess W4322758317 @default.
- W4322758317 hasPrimaryLocation W43227583171 @default.
- W4322758317 hasRelatedWork W1543124619 @default.
- W4322758317 hasRelatedWork W2027758774 @default.
- W4322758317 hasRelatedWork W2064548379 @default.
- W4322758317 hasRelatedWork W2123633897 @default.
- W4322758317 hasRelatedWork W2130365346 @default.
- W4322758317 hasRelatedWork W2137226206 @default.
- W4322758317 hasRelatedWork W2164845217 @default.
- W4322758317 hasRelatedWork W2585996010 @default.
- W4322758317 hasRelatedWork W2615765466 @default.
- W4322758317 hasRelatedWork W4246545933 @default.
- W4322758317 isParatext "false" @default.
- W4322758317 isRetracted "false" @default.
- W4322758317 workType "article" @default.